Last €56.17 EUR
Change Today +0.56 / 1.01%
Volume 1.0M
BN On Other Exchanges
Symbol
Exchange
OTC US
EN Paris
SIX Swiss Ex
OTC US
BrsaItaliana
Berlin
Mexico
As of 11:35 AM 11/27/14 All times are local (Market data is delayed by at least 15 minutes).

danone (BN) Snapshot

Open
€55.66
Previous Close
€55.61
Day High
€56.30
Day Low
€55.37
52 Week High
07/23/14 - €57.44
52 Week Low
01/31/14 - €48.33
Market Cap
36.2B
Average Volume 10 Days
1.4M
EPS TTM
€1.80
Shares Outstanding
643.8M
EX-Date
05/7/14
P/E TM
31.3x
Dividend
€1.45
Dividend Yield
2.58%
Current Stock Chart for DANONE (BN)

Related News

No related news articles were found.

danone (BN) Details

Danone produces and distributes food and beverage products. The company’s Fresh Dairy Products division provides yogurts, fermented fresh dairy products, and specialized dairy products under the Activia, Danonino, Fruchtswerge, Danoninho, Petit Gervais, Danimals, Serenito, Milkuat, Tëma, Actimel, Danacol, Densia, Oikos, Danio, Danette, Fantasia, Danissimo, YoCrunch, Vitalinea, Taillefine, and Ser brands. Its Waters division offers packaged natural, flavored, and vitamin-enriched water under Evian, Volvic, Bonafont, Mizone, Aqua, Fontvella, Lanjarón, Villavicencio, Villa del Sur, and Zywiec Zdroj brands. The company’s Early Life Nutrition division produces and distributes specialized food for babies and young children to complement breast-feeding, as well as solid foods for babies under Aptamil, Nutrilon, Almiron, Gallia, Bebelac, Cow&Gate, Blédina, and Malyutka brands. Its Medical Nutrition division provides specialized food for people receiving medical treatment, babies afflicted with certain illnesses, and frail elderly people. Its products include liquid oral nutritional supplements; hypoallergenic products; oral and feeding tube food products for the dietary treatment of infants and children who are incapable of feeding themselves or suffer from illness related malnutrition; and nutritional products for special medical needs. This division markets its products primarily under the Nutricia brand. The company serves individual consumers, retail chains, and traditional market outlets, as well as specialized distribution channels of hospitals, clinics, and pharmacies. It has operations in Russia, France, the United States, China, Indonesia, Spain, Mexico, Argentina, the United Kingdom, and Brazil. Danone has a strategic agreement with Starbucks to create and develop a line of Dannon-branded fresh dairy products. The company was formerly known as Groupe Danone and changed its name to Danone in April 2009. Danone was founded in 1899 and is based in Paris, France.

104,642 Employees
Last Reported Date: 03/24/14
Founded in 1899

danone (BN) Top Compensated Officers

Vice Chairman, Chief Executive Officer and Me...
Total Annual Compensation: €1.4M
Compensation as of Fiscal Year 2013.

danone (BN) Key Developments

Danone Reportedly Planning To Sell Yakult Stake

Danone (ENXTPA:BN) is planning to sell a stake in Yakult Honsha Co. Ltd. (TSE:2267). Bloomberg reported that Danone may sell 20% stake in Yakult Honsha for around $2 billion. According to the news report which citied people close to the matter, officials for Danone and Yakult were not immediately available to comment on the report. It further added that Danone has held internal discussions about a possible sale and the talks were at an early stage and no final decision has been made.

CVC Reportedly Interested In Medical Nutrition Business Of Danone

Fresenius SE & Co KGaA (DB:FRE) and Permira Investments Limited have made a joint bid for medical nutrition business of Danone (ENXTPA:BN), reported Wall Street Journal citing people familiar with the matter. The people said that new bid was submitted this week. According to some of the people, CVC Capital Partners Limited have also expressed interest in the assets. People familiar with the matter said that finding a strategic buyer for the medical nutrition business has been hampered by disagreements over price and antitrust hurdles that would arise with any combination. The people said, "Fresenius and Permira have been working to carve up the business between themselves to avoid the antitrust challenges, but the complexity is making a quick deal difficult." The people added that any deal would probably take until 2015. One of the people said, "[Danone] wants to know where it stands to either pursue talks and seal a deal by the end the of year or early next year or close the issue and move on."

Fresenius, Permira Reportedly Make Joint Bid For Danone’s Medical Nutrition Business

Fresenius SE & Co KGaA (DB:FRE) and Permira Investments Limited have made a joint bid for Danone (ENXTPA:BN)’s medical nutrition business, Wall Street Journal reported citing people familiar with the matter. The bid is for now the only one on the table, but Danone has set a deadline of early next week for any other parties to formalize their interest.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BN:FP €56.17 EUR +0.56

BN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Associated British Foods PLC 3,168 GBp +54.00
Baxter International Inc $72.40 USD -0.04
Fresenius SE & Co KGaA €43.58 EUR +0.69
Kraft Foods Group Inc $59.28 USD +0.34
Mondelez International Inc $39.00 USD +0.24
View Industry Companies
 

Industry Analysis

BN

Industry Average

Valuation BN Industry Range
Price/Earnings 28.2x
Price/Sales 1.4x
Price/Book 2.8x
Price/Cash Flow 30.9x
TEV/Sales 0.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DANONE, please visit www.danone.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.